Company Xilio Therapeutics, Inc.

Equities

XLO

US98422T1007

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
1.12 ^USD	-5.08%		-10.40%	+103.64%

Apr. 19	Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says	MT
Apr. 01	Xilio Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The Company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers). Its product pipeline includes XTX101, XTX301, XTX202, XTX501, and tumor-activated bispecific molecules and immune cell engager molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.

Number of employees: 73

Managers	Title	Age	Since
René Russo CEO	Chief Executive Officer	49	19-05-21
Kevin Brennan DFI	Director of Finance/CFO	54	-
Katarina Luptakova CTO	Chief Tech/Sci/R&D Officer	-	22-09-30
Christopher Frankenfield COO	Chief Operating Officer	42	21-02-28
Uli Bialucha CTO	Chief Tech/Sci/R&D Officer	-	21-03-31
Scott Coleman PRN	Corporate Officer/Principal	-	22-05-31
Stacey J. Davis PRN	Corporate Officer/Principal	-	22-05-16

Members of the board	Title	Age	Since
Paul Clancy CHM	Chairman	62	20-07-22
Daniel Curran BRD	Director/Board Member	57	20-11-30
Tomas Jan Heyman BRD	Director/Board Member	68	22-09-14
Sara Bonstein BRD	Director/Board Member	43	21-08-16
Robert Ross BRD	Director/Board Member	50	22-06-15
René Russo CEO	Chief Executive Officer	49	19-05-21
Christina Rossi BRD	Director/Board Member	48	21-03-31
Yuan Xu BRD	Director/Board Member	56	22-01-03

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	36,917,834	27,391,445 ( 74.20 %)	5,617 ( 0.0152 %)	74.20 %

Name	Equities	%	Valuation
GILEAD SCIENCES, INC. 19.90 %	7,345,473	19.90 %	7 M $
Rock Springs Capital Management LP 8.136 %	3,003,259	8.136 %	3 M $
Impresa Management LLC 5.168 %	1,907,671	5.168 %	2 M $
Octagon Capital Advisors LP 4.836 %	1,785,000	4.836 %	2 M $
MERCK & CO., INC. 4.019 %	1,483,414	4.019 %	1 M $
RiverVest Venture Management LLC 3.905 %	1,441,444	3.905 %	1 M $
Rock Springs Capital Management LP 3.903 %	1,440,759	3.903 %	1 M $
Atlas Venture Life Science Advisors LLC 2.690 %	992,912	2.690 %	1 M $
Vanguard Global Advisers LLC 2.445 %	902,531	2.445 %	911 556 $
Artal Group SA 1.219 %	450,000	1.219 %	454 500 $

Xilio Therapeutics, Inc.

828 Winter Street Suite 300

02451, Waltham

http://www.xiliotx.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.12 USD

Average target price

4.667 USD

Spread / Average Target

+316.67%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
XILIO THERAPEUTICS, INC.	+103.64%	41.34M
MODERNA, INC.	+26.37%	48.16B
IQVIA HOLDINGS INC.	-1.01%	41.73B
LONZA GROUP AG	+46.00%	41.03B
CELLTRION, INC.	-5.31%	28.77B
ICON PUBLIC LIMITED COMPANY	+9.34%	25.59B
ALNYLAM PHARMACEUTICALS, INC.	-21.69%	18.96B
BIO-TECHNE CORPORATION	+6.23%	12.92B
MEDPACE HOLDINGS, INC.	+26.99%	12.03B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.38%	11.77B

Other Biotechnology & Medical Research